| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/PCN.12072 |
| P698 | PubMed publication ID | 23890122 |
| P2093 | author name string | Irene Daum | |
| Patrizia Thoma | |||
| P2860 | cites work | Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. | Q52016145 |
| GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. | Q52023779 | ||
| Executive and motor skill functioning among cocaine-dependent schizophrenics and non-drug-abusing schizophrenics. | Q52121982 | ||
| Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS) | Q57655310 | ||
| Cerebellar volumes in men with schizophrenia and alcohol dependence | Q57832911 | ||
| Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients | Q57880912 | ||
| Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia | Q58190172 | ||
| Associations between past alcohol, cannabis, and cocaine use and current schizotypy among first-degree relatives of patients with schizophrenia and non-psychiatric controls. | Q46035668 | ||
| Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions | Q46250301 | ||
| Processing of social emotion in patients with schizophrenia and substance use disorder: an fMRI study | Q46478883 | ||
| Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients | Q46485919 | ||
| Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia | Q46568489 | ||
| Dysfunction of ventral striatal reward prediction in schizophrenia | Q46684383 | ||
| Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia | Q46783428 | ||
| Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia | Q46909505 | ||
| Exploring depression in schizophrenia | Q47341263 | ||
| Schizophrenia, sensory gating, and nicotinic receptors | Q48012124 | ||
| Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity | Q48118197 | ||
| Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood | Q48122360 | ||
| Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia | Q48257411 | ||
| Cerebellar gray matter volume correlates with duration of cocaine use in cocaine-dependent subjects | Q48273454 | ||
| Schizophrenia, substance use, and brain morphology | Q48283643 | ||
| Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia | Q48417817 | ||
| Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis | Q48655780 | ||
| Basal ganglia-thalamocortical circuitry disruptions in schizophrenia during delayed response tasks | Q48662967 | ||
| Patterns of current and lifetime substance use in schizophrenia | Q48715154 | ||
| Reasons for substance use in schizophrenia | Q48735768 | ||
| Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia | Q48909840 | ||
| Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. | Q51001917 | ||
| Cannabis use and cognitive functioning in first-episode schizophrenia patients. | Q51846635 | ||
| Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. | Q51888329 | ||
| Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence, and dual diagnosis. | Q51906881 | ||
| Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. | Q51918277 | ||
| Impairment of probabilistic reward-based learning in schizophrenia. | Q51927732 | ||
| The environment and schizophrenia: the role of cannabis use. | Q51928698 | ||
| Traumatic life events and PTSD among women with substance use disorders and schizophrenia. | Q51949602 | ||
| Working memory and depressive symptoms in patients with schizophrenia and substance use disorders. | Q51952571 | ||
| The role of cannabis in cognitive functioning of patients with schizophrenia. | Q51957715 | ||
| Working memory and multi-tasking in paranoid schizophrenia with and without comorbid substance use disorder. | Q51965512 | ||
| CANTAB explicit memory is less impaired in addicted schizophrenia patients. | Q51991798 | ||
| Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. | Q51995064 | ||
| Cannabis use and cognition in schizophrenia | Q37643444 | ||
| Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status | Q37693834 | ||
| Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. | Q37734568 | ||
| Treating comorbid substance use disorders in schizophrenia | Q37760932 | ||
| Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia | Q37925173 | ||
| Cocaine craving and attentional bias in cocaine-dependent schizophrenic patients | Q38418860 | ||
| Comorbid substance use and age at onset of schizophrenia | Q39747250 | ||
| The environment and schizophrenia | Q39958490 | ||
| Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia | Q40175951 | ||
| Fewer but heavier caffeine consumers in schizophrenia: a case-control study | Q40314519 | ||
| Anxiety and substance use comorbidity among inpatients with schizophrenia | Q40599145 | ||
| Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia | Q41890064 | ||
| Schizophrenia and smoking: an epidemiological survey in a state hospital | Q42280921 | ||
| Substance use disorders in schizophrenia--clinical implications of comorbidity | Q43145195 | ||
| Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder | Q43520161 | ||
| Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia | Q43638398 | ||
| Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients | Q43723165 | ||
| Cannabis induced dopamine release: an in-vivo SPECT study | Q43744306 | ||
| The effects of nicotine on specific eye tracking measures in schizophrenia | Q44174116 | ||
| Cognitive disparity in schizophrenics with and without cocaine dependency | Q44368428 | ||
| Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. | Q44413284 | ||
| Effects of alcohol dependence comorbidity and antipsychotic medication on volumes of the thalamus and pons in schizophrenia | Q44460081 | ||
| Substance misuse at presentation to an early psychosis program | Q44800166 | ||
| Nicotine effects on brain function and functional connectivity in schizophrenia | Q44819469 | ||
| Nicotine reduces antisaccade errors in task impaired schizophrenic subjects | Q44849187 | ||
| Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms | Q45049153 | ||
| Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults | Q45163957 | ||
| Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders | Q45215370 | ||
| Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder. | Q45961537 | ||
| A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors | Q22251463 | ||
| The self-medication hypothesis of substance use disorders: a reconsideration and recent applications | Q28255574 | ||
| Nicotine use in schizophrenia: the self medication hypotheses | Q28257325 | ||
| Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study | Q28259349 | ||
| Dual diagnosis: a review of etiological theories | Q28287738 | ||
| Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study | Q28301780 | ||
| A neurobiological basis for substance abuse comorbidity in schizophrenia | Q28347063 | ||
| Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients | Q28372074 | ||
| Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients | Q30425458 | ||
| Predictors of smoking severity in patients with schizophrenia and alcohol use disorders | Q30463995 | ||
| Are we dependent upon coffee and caffeine? A review on human and animal data | Q30559468 | ||
| Brain imaging and the effects of caffeine and nicotine | Q30633029 | ||
| The prefrontal cortex: insights from functional neuroimaging using cognitive activation tasks | Q30886627 | ||
| The neural circuitry of reward and its relevance to psychiatric disorders | Q30957200 | ||
| The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? | Q31149257 | ||
| Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. | Q31440279 | ||
| Frontal lobe changes in alcoholism: a review of the literature | Q31961062 | ||
| Compounded brain volume deficits in schizophrenia-alcoholism comorbidity | Q33186290 | ||
| Neurocognitive insights into substance abuse | Q33341050 | ||
| Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction | Q33626978 | ||
| Risk/reward decision-making in schizophrenia: a preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performance | Q33635728 | ||
| The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample | Q33641039 | ||
| Cortical-striatal integration of cocaine history and prefrontal dysfunction in animal modeling of dual diagnosis | Q33770817 | ||
| Prefrontal cortical volume reduction associated with frontal cortex function deficit in 6-week abstinent crack-cocaine dependent men. | Q33802542 | ||
| Substance use disorders in schizophrenia: review, integration, and a proposed model | Q33865680 | ||
| Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia | Q33932087 | ||
| Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia | Q33976751 | ||
| Cannabis use disorders in schizophrenia: effects on cognition and symptoms | Q33985743 | ||
| Why do patients with schizophrenia smoke? | Q34091154 | ||
| Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models | Q34098209 | ||
| An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results | Q34121866 | ||
| The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis | Q34172024 | ||
| Effects of caffeine on sleep and cognition | Q34181288 | ||
| Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis | Q34235419 | ||
| A national study of violent behavior in persons with schizophrenia | Q34519980 | ||
| Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions | Q34558070 | ||
| Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia | Q34604413 | ||
| Impulsivity and sensation seeking in alcohol abusing patients with schizophrenia | Q34689535 | ||
| It could be habit forming: drugs of abuse and striatal synaptic plasticity. | Q35104780 | ||
| Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia. | Q35175759 | ||
| The impact of substance use on brain structure in people at high risk of developing schizophrenia | Q35177137 | ||
| Frontal cortex as the central executive of working memory: time to revise our view. | Q35570674 | ||
| Allostasis and addiction: role of the dopamine and corticotropin-releasing factor systems | Q35783139 | ||
| Schizophrenia: diathesis-stress revisited | Q35898047 | ||
| Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder | Q36142165 | ||
| Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress | Q36213587 | ||
| Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? | Q36228225 | ||
| The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? | Q36228755 | ||
| Cognition in schizophrenia: impairments, determinants, and functional importance | Q36240811 | ||
| A meta-analysis of negative symptoms in dual diagnosis schizophrenia | Q36421120 | ||
| Reduced hippocampal volume among adolescents with alcohol use disorders without psychiatric comorbidity | Q36502059 | ||
| Chronic smoking and the BOLD response to a visual activation task and a breath hold task in patients with schizophrenia and healthy controls | Q36559599 | ||
| Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms | Q36696091 | ||
| The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia | Q36696097 | ||
| Smoking status as a potential confound in the BOLD response of patients with schizophrenia. | Q36959123 | ||
| The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues | Q36965847 | ||
| Molecular mechanisms of schizophrenia | Q36992703 | ||
| Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia | Q37063606 | ||
| Pharmacotherapy of schizophrenia with comorbid substance use disorder--reviewing the evidence and clinical recommendations | Q37131356 | ||
| Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia | Q37268687 | ||
| Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study | Q37310198 | ||
| Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand | Q37316109 | ||
| Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory | Q37336313 | ||
| Neurocognitive characteristics of individuals with schizophrenia and cocaine dependence: comparison of currently dependent and remitted groups | Q37421576 | ||
| Substance use and abuse in first-episode psychosis: prevalence before and after early intervention | Q37427095 | ||
| Prevalence of alcohol use disorders in schizophrenia--a systematic review and meta-analysis | Q37449097 | ||
| Use of caffeine and nicotine in people with schizophrenia | Q37561249 | ||
| P433 | issue | 6 | |
| P921 | main subject | schizophrenia | Q41112 |
| substance use disorder | Q7632070 | ||
| P304 | page(s) | 367-383 | |
| P577 | publication date | 2013-07-25 | |
| P1433 | published in | Psychiatry and Clinical Neurosciences | Q15760564 |
| P1476 | title | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings | |
| P478 | volume | 67 |
| Q90252559 | Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task |
| Q37459870 | Adolescent Social Isolation as a Model of Heightened Vulnerability to Comorbid Alcoholism and Anxiety Disorders. |
| Q92523805 | Analysis of the superior temporal gyrus as a possible biomarker in schizophrenia using voxel-based morphometry of the brain magnetic resonance imaging: a comprehensive review |
| Q49870570 | Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach |
| Q47599410 | Association of schizotypy with striatocortical functional connectivity and its asymmetry in healthy adults. |
| Q35243704 | Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). |
| Q47307661 | Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth |
| Q37598266 | Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. |
| Q93348798 | Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence |
| Q35109168 | Clinical predictors of therapeutic response to antipsychotics in schizophrenia |
| Q92238326 | Early Substance Use Cessation Improves Cognition-10 Years Outcome in First-Episode Psychosis Patients |
| Q36252880 | Executive Functioning in Men with Schizophrenia and Substance Use Disorders. Influence of Lifetime Suicide Attempts |
| Q47549679 | Genome-wide analysis of self-reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank cohort. |
| Q36579971 | Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes |
| Q94544886 | Metaphor Processing Dysfunctions in Schizophrenia Patients With and Without Substance Use Disorders |
| Q36815675 | Patterns of Substance Use During Cognitive Enhancement Therapy: An 18-Month Randomized Feasibility Study |
| Q52147043 | Perinatal Treatments with the Dopamine D₂-Receptor Agonist Quinpirole Produces Permanent D₂-Receptor Supersensitization: a Model of Schizophrenia. |
| Q91717997 | Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis |
| Q26801102 | Revisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior |
| Q30375488 | Searching human brain for mechanisms of psychiatric disorders. Implications for studies on schizophrenia. |
| Q93106702 | Sex-specific up-regulation of lncRNAs in peripheral blood of patients with schizophrenia |
| Q26742198 | Unraveling Executive Functioning in Dual Diagnosis |
| Q87927295 | What can we learn about brain donors? Use of clinical information in human postmortem brain research |
| Q52310900 | [Schizophrenia and addictions: dangerous links]. |
| Q30362464 | nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. |
Search more.